4.7 Meeting Abstract

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2018.36.15_suppl.9062

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available